Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection

Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection

Young-Mo Yang, Eun Joo Choi Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju, South Korea Background: Tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are recommended as the first-line therapy for chronic hepatitis B (CHB) due to their genetic barrier to resistance an...

Full description

Bibliographic Details
Main Authors:	Yang YM, Choi EJ
Format:	Article
Language:	English
Published:	Dove Medical Press 2017-09-01
Series:	Therapeutics and Clinical Risk Management
Subjects:	hepatitis B tenofovir entecavir renal safety
Online Access:	https://www.dovepress.com/renal-safety-of-tenofovir-andor-entecavir-in-patients-with-chronic-hbv-peer-reviewed-article-TCRM

Similar Items

Comparison of the effectiveness and renal safety of tenofovir versus entecavir in patients with chronic hepatitis B
by: Beatriz López Centeno, et al.
Published: (2016-07-01)

Virologic response and safety of tenofovir versus entecavir in treatment-naïve chronic Hepatitis B patients
by: Hyung Min Yu, et al.
Published: (2015-01-01)

Evaluation of the Efficacy of Entecavir and Tenofovir in the Treatment of Chronic Hepatitis B: A Retrospective Study
by: Arzu ŞENOL, et al.
Published: (2019-12-01)

Efficacia e sicurezza di entecavir dopo switch da tenofovir per comparsa di effetti collaterali renali: uno studio multicentrico italiano, di pratica clinica, su 103 pazienti con epatite cronica B
by: Mauro Viganò
Published: (2018-09-01)

Comparison of first-year results of tenofovir and entecavir treatments of nucleos(t)ide-naive chronic hepatitis B patients with hepatosteatosis
by: Zeynal Dogan, et al.
Published: (2015-01-01)

Analogs in the treatment of chronic hepatitis B: real life experience with tenofovir and entecavir
by: Rosanna Villani, et al.
Published: (2015-06-01)

Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir
by: Hee-Jeong Jeon, et al.
Published: (2017-09-01)

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
by: Sung Won Lee, et al.
Published: (2021-07-01)

Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?
by: Byoung Kuk Jang
Published: (2020-07-01)

Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
by: Norio Itokawa, et al.
Published: (2021-01-01)

Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B
by: Juan Li, et al.
Published: (2021-06-01)

A comparison between entecavir and tenofovir in chronic hepatitis B in the clinical practice: a single-center experience
by: Salvatore Sollima, et al.
Published: (2015-06-01)

Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study
by: Ayse Batirel, et al.
Published: (2014-11-01)

Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
by: Jung Gil Park, et al.
Published: (2015-09-01)

Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir
by: Nobuharu Tamaki, et al.
Published: (2020-06-01)

The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy
by: Jeong Han Kim, et al.
Published: (2016-06-01)

Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B
by: Young Min Kim, et al.
Published: (2018-01-01)

[Tenofovir and entecavir for chronic hepatitis B infection treatment: a single-center experience]
by: Fabio Tarsetti, et al.
Published: (2015-12-01)

Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations
by: Tanno Hugo, et al.
Published: (2011-06-01)

Resultados en la práctica clínica del tratamiento de la hepatitis crónica por virus B con tenofovir y entecavir
by: Diana Horta, et al.

Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries
by: Andrew Hill, et al.
Published: (2015-04-01)

Laboratory Evaluation of Three Regimens of Treatment of Chronic Hepatitis B: Tenofovir, Entecavir and Combination of Lamivudine and Adefovir
by: Rajeswari Jayakumar, et al.
Published: (2012-01-01)

Tenofovir Is Superior to Entecavir on Tertiary Prevention for BCLC Stage 0/A Hepatocellular Carcinoma after Curative Resection
by: Ming-Chao Tsai, et al.
Published: (2021-09-01)

Tenofovir Treatment Has Lower Risk of Hepatocellular Carcinoma than Entecavir Treatment in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis
by: Hairong Liu, et al.
Published: (2020-05-01)

Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores
by: Chen, L., et al.
Published: (2022)

Efficacy of different nucleoside analog rescue therapies for entecavir-resistant chronic hepatitis B patients
by: Jin Shang, et al.
Published: (2021-09-01)

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
by: Hyun Young Woo, et al.
Published: (2020-07-01)

Entecavir administration to pregnant Japanese woman with chronic hepatitis B and hepatocellular carcinoma: A case report
by: Toshihiko Kakiuchi, et al.
Published: (2021-03-01)

Compare with safety and efficacy of entecavir and adefovir dipivoxil combination therapy and tenofovir disoproxil fumarate monotherapy for chronic hepatitis B patient with adefovir-resistant
by: Ming-Chun Lai, et al.
Published: (2020-01-01)

Tenofovir Disoproxil Fumarate Is Superior to Entecavir in Reducing Hepatitis B Surface Antigen for Chronic Hepatitis B in China: 2-Year Comprehensive Comparative Result of a Matched Comparative Study
by: Sisi Yang, et al.
Published: (2021-03-01)

Comparative role of tenofovir versus entecavir for treating patients with hepatitis B virus-related acute on chronic liver failure
by: Sharker M. S. Hossain, et al.
Published: (2021-01-01)

Fanconi syndrome and chronic renal failure in a chronic hepatitis B monoinfected patient treated with tenofovir
by: Pedro Magalhães-Costa, et al.

Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice
by: Mireia Miquel, et al.
Published: (2013-03-01)

Comparison of Renal Safety of Tenofovir and Telbivudine in Chronic Hepatitis B Patients: A Real World Study in Indonesia
by: Rino Alvani Gani
Published: (2018-09-01)

Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study
by: Dae Won Jun, et al.
Published: (2013-06-01)

Comparison of entecavir and adefovir for the treatment of chronic hepatitis B
by: Si-Hai Zhao, et al.

Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?
by: Yun Bin Lee, et al.
Published: (2017-09-01)

Prevention of Hepatitis B Virus Reactivation in Kidney Transplant Recipients
by: H Nasri, et al.
Published: (2016-04-01)

Experience of entecavir therapy in chronic hepatitis B
by: E. V. Esaulenko, et al.
Published: (2014-09-01)

Entecavir Treatment in Children and Adolescents with Chronic Hepatitis B Virus Infection
by: Kai-Chi Chang, et al.
Published: (2016-10-01)